頭頸部扁平上皮癌におけるCYFRAとSCC抗原・TPAとの比較・検討:―新しい腫瘍マーカーCYFRAの臨床応用性について― Comparison of CYFRA to SCC antigen, TPA for Head Neck Squamous Cell Carcinomas:—Clinical Efficiency of New Tumor Marker CYFRA—
Access this Article
頭頸部扁平上皮癌新鮮例38例を対象にして,CYFRAとSCC抗原,TPAを比較,検討した。コントロールには非癌症例21例を用いた。CYFRAについては臨床経過を観察できた頭頸部扁平上皮癌20例についても検討した。各腫瘍マーカーの感度と特異度はCYFRAが63.2%と95.2%(cut off値1.1ng/ml),SCC抗原は52.6%と95.2%(cut off値1.1ng/m1),TPAは68.4%と100%(cutoff値50U/L)であった。CYFRAはSCC抗原と同等以上の有用性を有するが,TPAより若干劣っていると思われる。CYFRAは頭頸部扁平上皮癌の臨床経過をある程度反映すると思われる。
We examined the clinical efficiency of the new tumor marker CYFRA for head and neck squamous cell carcinomas and compared it with SCC antigen and TPA. The cut off values were as follows : CYFRA at 1.1 ng/ml, SCC 1.1 ng/ml and TPA 50 U/L. The sensitivity and the specificity of CYFRA were 63.2 % and 95.2 %, respectively. The sensitivity and the specificity of SCC antigen were 52.6 % and 95.2 %, respectively. The sensitivity and the specificity of TPA were 68.4 % and 100 %, respectively. TPA showed the highest positive rate on head neck squamous cell carcinomas and CYFRA was the second. As tumors progressed we found a tendency in that the positive rate of all tumor makers, rise. There was a strong correlation between CYFRA and SCC antigen and also between CYFRA and TPA. The positive rate on combination assay of SCC antigen and TPA was 78.9 %, which was the highest. Therefore, we conclude that CYFRA was a better tumor marker than SCC antigen and TPA was a best tumor marker for screening head neck squamous cell carcinomas. We expect CYFRA to be useful for follow-up because it reflects the stage of the disease.
- JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY 6(3), 173-179, 1996
JAPAN SOCIETY FOR HEAD AND NECK SURGERY